NCT06232083View on ClinicalTrials.gov

A Multi Tumor, Open Phase I Clinical Study on the Progression of First-line Anti-tumor Therapy Using Cardonizumab Combined With Pulsed Low-dose Rate External Irradiation (PLDR)

PHASE1RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

September 1, 2025

Primary Completion Date

June 30, 2027

Study Completion Date

September 1, 2027

Conditions
Lung CancerEsophageal CancerCervical Cancer
Interventions
RADIATION

PLDR+Cardunizumab

Application of PLDR external irradiation combined with Cardunizumab in recurrent lung cancer, esophageal cancer and cervical cancer.

Trial Locations (1)

230001

RECRUITING

The First Affiliated Hospital of University of Science and Technology of China, Hefei

Sponsors
All Listed Sponsors
collaborator

Akeso Pharmaceuticals, Inc.

OTHER

lead

Anhui Provincial Hospital

OTHER_GOV